Metropolis Healthcare posts Q1 FY25 at Rs. 38.1 Cr
Revenue from operations stood at Rs. 313.4 crore during Q1 FY25
Revenue from operations stood at Rs. 313.4 crore during Q1 FY25
Our centers are performing as expected or even better
The International Society of Aesthetic Plastic Surgery reported that non-surgical procedures outnumbered surgical ones globally in 2020
Revenue from Operations increased by 10.5% YoY to Rs. 7,567 crore with growth across the businesses
The company has seamlessly integrated the business acquired from Yash Pharma into Jagsonpal and are now confident of aligning the margins of the acquired business with that of Jagsonpal ahead of schedule
The pharma market is showing encouraging signs of improvement, positioning us well for future growth
Expect the international business including CDMO business to pick-up in the second half of the financial year
Organization to provide vaccinations & treatments for several monsoon related diseases and illnesses across all 102 clinics
The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
The acquisition of LumiraDx’s Point of Care technology received all required antitrust and regulatory clearances
Subscribe To Our Newsletter & Stay Updated